Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity

Roberto Angioli1, Michela Angelucci1,*, Francesco Plotti1, Corrado Terranova1, Roberto Montera1, Patrizio Damiani1, Ester Valentina Cafa1, Pierluigi Benedetti Panic1 and Angiolo Gadducci1

1Department of Obstetrics and Gynecology Campus Bio Medico University of Rome, Rome, Italy
2Department of Obstetrics and Gynecology, “Sapienza” University of Rome, Rome, Italy
3Department of Obstetrics and Gynecology, University of Pisa, Rome, Italy

Abstract

Introduction: Pegylated liposomal doxorubicin (PLD) is considered to be the single-agent of first choice for patients with recurrent ovarian cancer following paclitaxel/carboplatin-based chemotherapy. However, this drug is associated with a local inflammatory tissue reaction, called palmoplantar erythrodysesthesia (PPE). A new liposomal formulation, known as Liposome Encapsulated Doxorubicin Citrate (LEDc), has been developed in the past decades to limit PPE. In this study we report our experience with LEDC in patients with recurrent ovarian cancer who discontinued doxil due to severe PPE.

Methods: The present retrospective study included 43 patients with recurrent ovarian cancer who were treated with LEDC administered at the dose of 50 mg/m2 every 3 weeks until disease progression or unacceptable toxicity. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 3. Response was graded according to Response Evaluation Criteria in Solid Tumors (RECIST).

Results: A total of 32 patients completed planned 6 cycles of chemotherapy. A complete response was achieved in 6%, partial response in 20%, stable disease in 37% and progression in 9% of patients. No cutaneous toxicity was reported.

Conclusion: LEDC is a well tolerated drug and a valid therapeutic option for patients with ovarian cancer suffering from doxil-related cutaneous toxicity.

Keywords: Cutaneous toxicity; Chemotherapy; Refractory disease; Ovarian cancer

Introduction

In spite of recent progress in treatment strategies, 70% of advanced stage ovarian cancer cases relapse [1]. Patients with recurrent disease are commonly characterized as platinum sensitive or platinum resistant. The definition of platinum-resistant disease includes patients who progress while receiving initial chemotherapy or within 6 months of completing initial platinum-based chemotherapy. If platinum free interval is less than 3-month, patients are defined as refractory disease and they have very little chance to respond to a platinum-based therapy.

Platinum-sensitive patients are defined by recurrence after 6 or more months of the completion of initial chemotherapy. For a better subdivision of platinum sensitive group, patients with a more than 12-month interval are defined as highly sensitive disease and patients with 6 to 12 months are considered intermediate sensitive disease. Response to platinum retreatment increases with a longer interval from prior platinum treatment.

Whereas combination treatment with a platinum-doublet is frequently used for recurrent platinum-sensitive patients, especially those with a prolonged disease-free interval, numerous agents are available that can be used as single-agent therapy. Epirubicin, Etoposide, Topotecan, Gemcitabine and Pegylated Liposomal Doxorubicin [2-6] are some of the single-agent treatment options. Single-agent treatment is currently the preferred approach for platinum-resistant patients with a response rate ranging from 9% to 33%. The goal of treatment in these patients is controlling the disease and the disease-related symptoms, limiting treatment-related toxicity and maintaining or improving quality of life. Therefore, toxicity profile of these drugs is crucial.

Anthracyclines have demonstrated cytotoxic activity in advanced ovarian cancer. Response rate is between 14% and 20% [2,7]. Despite its efficacy substantial toxicity related to its myelosuppressive and cardiotoxic effects has limited its use [8].

Pegylated liposomal doxorubicin (PLD) has been developed to obtain equal benefit without the several side effects of doxorubicin [9,10]. Pegylation of liposomal capsules alters the pharmacokinetic profile, decreasing volume of distribution and extending circulation time [11].

Phase 2 studies established PLD to be an active cytotoxic agent in platinum refractory ovarian cancer when administered at a dose of 50 mg/m2 every 3 weeks [12]. At this dosage, however, the most common grade 3-4 non hematological toxicities associated with PLD were

*Corresponding author: Michela Angelucci, Department of Obstetrics and Gynecology, University of Rome “Campus Bio-Medico”, Via Álvarez del Portillo, 200 - 00128 Rome, Italy, E-mail: m.angelucci@unicampus.it

Received May 29, 2013; Accepted June 20, 2013; Published June 24, 2013

Citation: Angioli R, Angelucci M, Plotti F, Terranova C, Montera R, et al. (2013) Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity. Chemotherapy 2: 113. doi:10.4172/2167-7700.1000113

Copyright: © 2013 Angioli R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The performance status assessment was performed using the criteria of the Eastern Cooperative Oncology Group (ECOG) score [17]. Measurable disease was defined as lesions measured by means of imaging techniques (CT scan; MRI) as recommended by the protocol of Response Evaluation Criteria in Solid Tumors (RECIST), complete response was defined as a lesion major diameter reduction of 30%. A decrease or increase in size below 30% in absence of new lesions diagnosis was defined as stable disease. An increase of more than 30% or the appearance of new lesions were defined as progressive disease. Clinical response duration or steady disease duration were calculated from the beginning of the treatment to the diagnosis of progression.

Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 3 during treatment, complete blood cell count, differential, and platelet count were repeated at 7th, 11th, 15th days after chemotherapy cycle and hematologic toxicity grading was based on nadir counts. Blood chemistry analyses were performed on the 15th day after chemotherapy. A dose reduction of 25% was performed when a grade III-IV hemato logic toxicity was observed [19].

Chemotherapy was discontinued if toxicity lasted longer than 2 weeks. Cardiac toxicity was based on echocardiographic left ventricular ejection fraction (LVEF) measurements and a 12-lead electrocardiogram that were performed at baseline and every 12 weeks (3 months) [20].

### Results

Table 1 summarizes patients characteristics. The median age was 65 (range 42-79), most patients (83%) had performance status 0, forty patients were affected by recurrent disease, while 3 patients had metastatic disease. Most common sites of relapse were peritoneum (51%) and pelvis (34%). Platinum sensitive patients are 34 (80%), platinum resistant patients are 7 (16%) and partial platinum sensitive are 2 (4%).

After initial three cycles of chemotherapy, 3 out of 43 patients showed a complete response (6%), 9 patients showed a partial response.

### Patients and Methods

We have retrospectively assessed 43 patients who developed PPE during doxil-based chemotherapy for recurrent epithelial ovarian cancer from January 2000 to December 2008 at Policlinico Campus Bio Medico, Department of Reproductive Medicine, Division of Gynecology and Obstetrics, University of Pisa, and Department of Gynecology, Perinatology and Pediatric Nursing of Policlinico Umberto I University “La Sapienza” of Rome. The study has been approved by a Policlinico Campus Bio Medico ethics committee.

Eligibility criteria were: two or more prior chemotherapy regimens; discontinuation of a previous regime due to grade III-IV palmar-plantar erythrodysesthesia (PPE); presence of measurable disease; adequate organ function (as evidenced by white blood cell count of 3000/KL or greater, granulocyte count of 1000/KL or greater, platelet count of 100,000/KL or greater, creatinine level of 2.0 mg/100 mL or less, bilirubin level of 1.5 times the institutional normal or less); no previous or concurrent other malignancy; performance status ≤ 2. The performance status assessment was performed using the ECOG (Eastern Cooperative Oncology Group) score [17]. Measurable disease was defined as lesions measured by means of imaging techniques (CT scan; MRI) as recommended by the protocol of Response Evaluation Criteria in Solid Tumors [18].

Patients enrolled in this study received a first-line treatment with carboplatinum. Platinum-sensitive disease was defined as a response to initial platinum-based therapy followed by a progression-free interval of 12 months. Platinum-resistant disease was defined as progression or stable disease during the initial platinum-based therapy or relapse within 6 months after completion of platinum-based therapy. Partial platinum sensitivity was defined as a progression between 6-12 months after completion of chemotherapy.

All patients enrolled in the study were treated with Liposomal Encapsulated Doxorubicin Citrate (LEDC). LEDC was administered intravenously over 1 hour-period at the dose of 50 mg/mq every 3 weeks until disease progression or unacceptable toxicity.

Tumor response was assessed every three chemotherapy cycles (three weeks after the last administration) by means of imaging techniques according to the target lesion site (CT scan; MRI) and of blood dosage of CA125. According to Response Evaluation Criteria in Solid Tumors (RECIST), complete response was defined as a disappearance of all target lesions. Partial clinical response was defined as a lesion major diameter reduction of 30%. A decrease or increase in size below 30% in absence of new lesions diagnosis was defined as stable disease. An increase of more than 30% or the appearance of new lesions were defined as progressive disease. Clinical response duration or steady disease duration were calculated from the beginning of the treatment to the diagnosis of progression.

### Table 1: Characteristics of patients

| Characteristics                  | Number of patients |
|----------------------------------|--------------------|
| Number of patients               | 43                 |
| Median Age (range)               | 65 (42-79)         |
| ECOG performance status, n (%)   |                    |
| 0                                | 36 (83)            |
| 1                                | 7 (16)             |
| 2                                |                    |
| Metastatic Ovarian Cancer, n (%) | 3 (6)              |
| Recurrent Ovarian Cancer, n (%)  | 40 (94)            |
| Platinum Sensitive, n (%)        | 34 (80)            |
| Platinum Resistant, n (%)        | 7 (16)             |
| Partial Platinum Sensitive, n(%) | 2 (4%)             |
| Site of Relapse, n (%)           |                    |
| Lung                             | 2 (4)              |
| Liver                            | 5 (11)             |
| Peritoneum                       | 15 (34)            |
| Pelvis                           | 13 (30)            |
| Retroperitoneum                  | 8 (19)             |
| Previous CT lines, n (%)         |                    |
| IL line                          | 4 (9%)             |
| II line                          | 29 (67%)           |
| III line                         | 10 (23%)           |
| Previous Side Effects, n (%)     |                    |
| PPE                              | 43 (100%)          |
all of patients. (20%), 21 patients (46%) achieved a stable disease and 10 patients (23%) had progressive disease. These latter stopper LEDC treatment and received other palliative chemotherapy. No treatment-related deaths were recorded. The most common toxicity was myelosuppression. G1, G2, G3 neutropenia occurred in 23%, 34%, 11% of the patients, respectively (Table 2), and only one patient (2%) suspended the treatment for febrile neutropenia G4. Therefore we excluded this patient from the study and then she was submitted to different schedules of palliative chemotherapy. Moreover G1 and G2 anaemia were encountered, respectively, in 12 (27%) and in 10 (23%) patients. G3 anaemia was observed in only 2 patients (5%). The nadir counts were observed more frequently at the 15th day after chemotherapy.

In 7 (16%) patients the dose was reduced by 25% after neutropenia or G3 anemia. No cutaneous toxicity was reported. There were no episodes of cardiac dysfunction (>10% reduction in ejection fraction) in all of patients. Overall toxicity profile after 3 cycles is showed in Table 2.

Patients with complete, partial or stable disease were treated with 3 successive cycles of LEDC, followed by disease reevaluation. Thus a total of 32 patients (74%) completed the planned 6 cycles of chemotherapy. After 6 cycles of chemotherapy, 3 out of 43 patients (6%) continued to show a complete response, 9 patients (20%) evidenced partial response, 16 patients (37%) showed stable disease and 4 patients (9%) suffered disease progression.

No severe G3–G4 hematologic toxicity was showed in this group, but neutropenia and anemia continued to be the most common side effects after 6 cycles of LEDC. In particular G1 neutropenia was encountered in 20 patients (46%) and G2 neutropenia was encountered in 15 patients (34%). G1 anaemia was encountered in 22 patients (51%) and G2 only in 10 patients (23%).

There were no episodes of G3-G4 toxicity in all of patients (Table 3). No cutaneous toxicity were reported. There were no episodes of cardiac dysfunction (>10% reduction in baseline ejection fraction) in all of patients.

**Discussion**

Advances in the treatment of ovarian cancer over the past decade, have led to emphasize the concept of managing ovarian cancer as a chronic disease. Indeed, patients are generally undergo a series of treatments, associated with progressively treatment-free intervals, with an increased median survival but a long-term management of these patients [21].

Treatment of patients with metastatic or recurrent ovarian cancer is often palliative. The value of a second-line therapy and its impact on survival is very poor [22]. Many active agents such epirubicin (2), etoposide (3), topotecan (4), gemcitabine (5) and pegylated liposomal doxorubicin (6) show response rate ranging from 9% to 33%, but prolonged remissions are uncommon. The goal of treatment in these patients is controlling the disease and the disease-related symptoms, limiting treatment-related toxicity and maintaining or improving quality of life. Therefore, toxicity profile of these drugs is crucial.

Pegylated liposomal doxorubicin (PLD) is considered to be the single agent of first choice for patients with recurrent ovarian cancer following paclitaxel/carboplatin based chemotherapy, when administered at a dose of 50 mg/m² every 3 weeks [6,10]. Because of its size, PLD extravasates through endothelial cells of tumor vasculature. This property, combined with its longer half-life, promotes targeted drug delivery to the tumor site but extravasation may occur in other areas of microvascular permeability, in particular from the microcapillaries of the hands and feet. This local accumulation may cause a skin inflammatory reaction, called PPE, often requiring dose reduction and/or treatment delays [23].

In the mid-1980s, the Lyposome Company developed LEDC, a stable, non pegylated liposomal formulation of doxorubicin. The strategy that allowed doxorubicin to be loaded into relatively small liposomes (150 nm) is a mechanism of passive encapsulation. Sodium carbonate was added to an aqueous suspension of liposome in a proton rich environment (citrate buffer) creating a pH of 7.8 outside the liposome and pH 4 within the liposome. When doxorubicin was added to these liposomes, its accumulation to the vesicle interior was driven by the lower internal pH since the doxorubicin formed a unique complex with citrate anions in the vesicle interior [19]. Liposomal entrapment alters the pharmacokinetics of doxorubicin and allows targeted chemotherapy as demonstrated in previous studies, where accumulation of LEDC in tumour tissue was more persistent than that conventional doxorubicin or PLD.

Compared to PLD, LEDC has a reduced half-life compared to recently reported for PLD [24]. This difference in half-life between LEDC and PLD is likely to contribute to the difference in toxicity profiles between the two formulations, such as reduction of PPE frequency and/or severity, and reduction of cardiac toxicity. The combination of LEDC plus cyclophosphamide showed a better therapeutic index, with reduced cardiotoxicity, reduced myelotoxicity and similar antitumor activity, when compared with the combination of PLD plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer [25]. Grade 3-4 PPE, which is a dose limiting toxicity with PLD, was not observed in LEDC treated patients.

Only one study in gynecologic oncology showed activity of LEDC at dose of 75 mg/m² every 3 weeks in advanced/recurrent gynecological cancer patients, with an overall response rate of 17% with a duration of response of 27 weeks. In particular the drug obtained a partial response and a stabilization of disease in 20% and 33%, respectively,

| Side Effects                      | G1 | G2 | G3 | G4 |
|-----------------------------------|----|----|----|----|
| Neutropenia                       | 10 (23%) | 15 (34%) | 5 (11%) | 1 (2%) |
| Anemia                            | 12 (27%) | 10 (23%) | 2 (5%) | - |
| Thrombocytopenia                  | 3 (7%) | 2 (5%) | - | - |
| Nausea and Vomiting               | 6 (14%) | 2 (5%) | - | - |
| Cutaneous                         | - | - | - | - |
| Stomatitis                        | - | - | - | - |
| Alopecia                          | 5 (11%) | 16 (37%) | - | - |
| Cardiac (reduction of EF>10%)     | - | - | - | - |

Table 2: Side Effects after 3 cycles of LEDC.
of patients with recurrent ovarian cancer. Treatment with LEDC in these patients was well tolerated: only one patient developed PPE (G3), while hematologic toxicity G3-G4 was encountered in 22 patients of 36 (22%). Only two patients (11%) suspended therapy following an episode of febrile neutropenia and nine patients (50%) required a dose reduction of 25% for hematologic toxicity. As a result, the next 18 patients were treated at a reduced dose 60 mg/m² of LEDC [16].

Thus in the management of ovarian cancer there is not a standard dosage of LEDC. In previous study on gynecologic malignancies [16] the authors used LEDC at dose of 75 mg/m² every 3 weeks. In consideration of their hematologic toxicity noticed in this study we decide to use LEDC at dose of 50 mg/m² every 3 weeks.

Therefore, the aim of our study was to investigate the toxicity profile, especially in terms of dermatological toxicity, of LEDC administration at the dose of 50 mg/m² q21 in a population of metastatic/recurrent ovarian cancer patients, who discontinued previous CT regimen due to severe PPE.

In our study a total of 32 patients (74%) completed the planned 6 cycles of chemotherapy.

Concerning response rate, our study shows that after 6 cycles of LEDC, 3 out of 32 patients (9%) showed a complete response, 9 patients (28%) evidenced partial response, 16 patients (50%) showed stable disease and 4 patients (12%) suffered disease progression. These results are positive if compared to the data reported in the literature with other second-line agents [4,6].

Moreover, the toxicity profile of LEDC appears to be very promising. Only one patient stopped the treatment because of severe neutropenia, and no patients developed cardiac dysfunction, cutaneous toxicity, or stomatitis.

The main toxicities associated with topotecan are haematological, including neutropenia, thrombocytopenia and anaemia. Markman et al firstly evaluated topotecan at the dose of 1.5 mg/m² days 1-3 q3 weeks in a population of 29 recurrent ovarian cancer patients [26]. Severe neutropenia occurred in 24% of patients. In a phase III randomized trial, patients were randomized to receive topotecan 1.5 mg/m² for 5 days vs paclitaxel 175 mg/m² day 1 every weeks [4]. This study demonstrated a significant benefit in the group treated with topotecan in terms of time to progression (23 weeks vs. 14 weeks) while high hematological toxicity was registered. Neutropenia was significantly more frequent on the topotecan arm 79% versus paclitaxel arm 23% (P<0.1).

PPE and mucositis are the most common serious side-effects of pegylated liposomal doxorubicin. Conversely, mielotoxicity and especially severe neutropenia, often occurs in patients treated with topotecan [27], and PPE and mucositis are common serious side-effects in those treated with PLD [28,29].

Conclusions

In this first report of LEDC in the treatment of metastatic-recurrent ovarian malignancies, toxicity data are very encouraging. In fact, despite its efficacy on ovarian cancer, PLD causes a severe cutaneous toxicity called palmar plantar erythrodysesthesia requiring often dose reduction or treatment delays. PPE is an invalidating cutaneous toxicity reaction that severely reduces the quality of life of patients.

Only our previous study has been conducted on use of LEDC in gynecological malignancies, showing promising results in terms of disease control and toxicity rate [16].

This is the first study that aimed at assessing the efficacy and safety of LEDC in treating recurrent metastatic ovarian cancer in patients. In our study LEDC was generally well tolerated even in patients forced to suspend previous chemotherapy protocols because of several cutaneous side effects. In conclusion, our results indicate that the use of LEDC is a well tolerated drug and a valid alternative in patients affected by ovarian cancer suffering from cutaneous toxicity by other drugs.

References

1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, et al. (2006) Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95: S161-192.
2. Vermorken JB, ten Bokkel Huinink WW, Kibierska A, van der Burg ME, Forni M, et al. (1999) Phase I study of high-dose epirubicin in platinum-preempted patients with ovarian carcinoma. Oncology 57; 10-16.
3. Rose PG, Blessing JA, Mayer AR, Hamesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405-410.
4. ten Bokkel Huinink W, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian cancer. Ann Oncol 15: 100-103.
5. Lund B, Hansen OP, Thelade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533.
6. Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8.
7. Pelazész I, Lacave AJ, Palacio I, Alvarez E, Cueva JF, et al. (1996) Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 32A: S999-S900.
8. Bristow MR, Mason JW, Billingham ME, Daniels JR (1981) Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102: 709-718.
9. Uziely B, Jeffers S, Isacon K, Rutsch K, Wei-Tsao D, et al. (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785.
10. Thigpen JT, Aghaajanian CA, Alberts DS, Campos SM, Gordon AN, et al. (2005) Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96: 10-18.
11. Woodle MC, Collins LR, Sponser I, Kossovsky N, Papahadjopoulos D, et al. (1992) Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophy J 61: 902-910.
12. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, et al. (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993.
13. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 85: 6949-6953.
14. Baltis G, Barton J, Chailkin P, Swenson C, Welles L (2002) Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 3: 1739-1751.
15. Baltis G (2007) Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 7: 72-74.
16. Angioli R, Palaia I, Calcagno M, Manci N, Zullo MA, et al. (2007) Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies. Int J Gynecol Cancer 17: 88-93.
17. Oken MM, Creech RR, Torrney DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655.
18. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quin M, et al. (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 419-423.

Citation: Angioli R, Angelucci M, Plot F, Terranova C, Montera R, et al. (2013) Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity. Chemotherapy 2: 113. doi:10.4172/2167-7700.1000113
19. DeVita VT (1997) Principles of cancer management: chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, (5thedn). Philadelphia: Lippincott-Raven, 333-347.

20. Jannazzo A, Hoffman J, Lutz M (2008) Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 42: 99-104.

21. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5: 20-28.

22. Tummala MK, McGuire WP (2005) Recurrent ovarian cancer. Clin Adv Hematol Oncol 3: 723-736.

23. Kim RJ, Peterson G, Kulb B, Zanotti KM, Markman M (2005) Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 97: 374-378.

24. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, et al. (2003) Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14: 239-246.

25. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Guthel J, et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5): 1444-1454.

26. Markman M, Kennedy A, Webster K, Kulb B, Peterson G, et al. (2000) Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79: 116-119.

27. Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, et al. (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74: 163-174.

28. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322.

29. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, et al. (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-3329.

Submit your next manuscript and get advantages of OMICS

Group submissions

Unique features:
- User friendlyfeasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing on PubMed (indexed), Scopus, DBLO, Index Copernicus and Google Scholar etc
- Sharing Options Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.omicsonline.org/submission/